Kartos Therapeutics is a privately held, clinical-stage biopharmaceutical company developing a potentially best-in-class MDM2 inhibitor. Launched in 2018 by proven industry veterans, we are a passionate team based in Redwood City, California, and Bellevue, Washington. We have brought together scientists and clinicians with a deep understanding of hematology and oncology and an experienced leadership team. Together, we’re building an exciting biotechnology company with a culture defined by caring, ambition, dedication, and teamwork! (Source: https://www.kartosthera.com)